A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Required: MUC16 expression by IHC

tumor tissue (archival or fresh) available for testing MUC16 expression by immunohistochemistry inclusion (IHC)

Must have received: standard of care treatment for advanced or metastatic NSCLC — first line

Has received appropriate first line standard of care treatment for advanced or metastatic NSCLC

Must have received: platinum-based chemotherapy

If platinum doublet chemotherapy was not administered as first line therapy, it is required in a later line of therapy prior to enrollment unless there is a documented reason why it is not appropriate

Cannot have received: anti-PD-1 therapy

Has progression of disease fewer than 84 days from starting initial anti-Programmed Cell Death (PD)-(L) 1 therapy

Cannot have received: anti-PD-1 therapy

Has received prior monoclonal antibody against PD-(L)1 within 21 days of the first dose of study intervention

Cannot have received: immunotherapy

Has had other prior anti-cancer immunotherapy within 21 days prior to study intervention

Cannot have received: cytotoxic chemotherapy

Has received prior cytotoxic chemotherapy within 21 days of the first dose of study intervention

Cannot have received: anti-EGFR antibody therapy

Has received an anti-EGFR antibody therapy within the following drug-specific window prior to first dose of study intervention (approximately 5 half-lives)